MedTrace Logo

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

NCT06770543 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-12-22

No results posted yet for this study

Summary

This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran sodium) in routine clinical practice for the approved indications (primary hypercholesterolemia or mixed dyslipidemia).

Conditions

  • Primary Hypercholesterolemia or Mixed Dyslipidemia

Interventions

OTHER

Inclisiran

There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-13
Primary Completion
2031-01-02
Completion
2031-01-02

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06770543 on ClinicalTrials.gov